218 Shares in Intuitive Surgical, Inc. (NASDAQ:ISRG) Purchased by EdgeRock Capital LLC

EdgeRock Capital LLC bought a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 218 shares of the medical equipment provider’s stock, valued at approximately $74,000.

Several other institutional investors have also modified their holdings of ISRG. WCM Investment Management LLC purchased a new position in shares of Intuitive Surgical during the fourth quarter valued at approximately $575,536,000. International Assets Investment Management LLC lifted its position in Intuitive Surgical by 32,360.5% during the fourth quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock worth $231,721,000 after buying an additional 684,749 shares during the period. Alphinity Investment Management Pty Ltd boosted its stake in Intuitive Surgical by 113.2% in the 4th quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock worth $430,525,000 after buying an additional 677,455 shares during the last quarter. J.P. Morgan Private Wealth Advisors LLC acquired a new position in shares of Intuitive Surgical during the 3rd quarter valued at about $178,667,000. Finally, Quadrature Capital Ltd boosted its position in shares of Intuitive Surgical by 466.2% in the third quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock worth $99,601,000 after acquiring an additional 280,480 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on ISRG. Mizuho boosted their price objective on shares of Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a research note on Thursday, January 25th. Wells Fargo & Company lifted their price target on shares of Intuitive Surgical from $363.00 to $416.00 and gave the company an “overweight” rating in a research report on Friday, January 19th. Truist Financial lifted their target price on shares of Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a report on Wednesday, January 24th. Piper Sandler increased their price target on Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a report on Friday, April 19th. Finally, Stifel Nicolaus increased their target price on Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a research note on Monday, April 8th. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat, Intuitive Surgical currently has an average rating of “Moderate Buy” and an average price target of $396.17.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 20,296 shares of Intuitive Surgical stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $393.80, for a total value of $7,992,564.80. Following the transaction, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at approximately $2,168,656.60. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, EVP Robert Desantis sold 20,296 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $393.80, for a total transaction of $7,992,564.80. Following the sale, the executive vice president now owns 5,507 shares in the company, valued at $2,168,656.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark J. Rubash sold 1,709 shares of the company’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $380.00, for a total transaction of $649,420.00. Following the transaction, the director now owns 16,051 shares in the company, valued at approximately $6,099,380. The disclosure for this sale can be found here. Insiders sold 147,927 shares of company stock worth $57,064,459 over the last ninety days. Company insiders own 0.80% of the company’s stock.

Intuitive Surgical Trading Down 2.1 %

NASDAQ:ISRG traded down $8.28 during trading hours on Wednesday, hitting $380.37. 1,107,969 shares of the stock traded hands, compared to its average volume of 1,601,620. The firm has a market cap of $134.92 billion, a price-to-earnings ratio of 68.66, a PEG ratio of 4.93 and a beta of 1.39. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $403.76. The firm has a 50 day moving average price of $385.34 and a 200 day moving average price of $351.97.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The firm had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. During the same quarter in the prior year, the business earned $1.00 earnings per share. The company’s revenue was up 11.5% on a year-over-year basis. Research analysts predict that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.